Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Caribou Biosciences, Inc. - Common Stock
(NQ:
CRBU
)
1.690
-0.100 (-5.59%)
Streaming Delayed Price
Updated: 1:00 PM EST, Dec 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,102,798
Open
1.790
Bid (Size)
1.710 (1)
Ask (Size)
1.760 (2)
Prev. Close
1.790
Today's Range
1.650 - 1.805
52wk Range
1.500 - 8.330
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
November 26, 2024
Via
Benzinga
Caribou Biosciences to Participate in Upcoming Investor Conferences
November 20, 2024
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Performance
YTD
-69.66%
-69.66%
1 Month
-16.34%
-16.34%
3 Month
-11.98%
-11.98%
6 Month
-3.98%
-3.98%
1 Year
-72.56%
-72.56%
More News
Read More
Caribou Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
November 06, 2024
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024
September 25, 2024
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Expert Ratings For Caribou Biosciences
September 03, 2024
Via
Benzinga
Caribou Biosciences Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
August 14, 2024
Via
Benzinga
Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML
September 03, 2024
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Caribou Biosciences to Participate in Upcoming Investor Conferences
August 26, 2024
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer
August 12, 2024
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
August 06, 2024
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Evaluating Caribou Biosciences: Insights From 4 Financial Analysts
July 17, 2024
Via
Benzinga
Cracking The Code: Understanding Analyst Reviews For Caribou Biosciences
June 04, 2024
Via
Benzinga
Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board
July 09, 2024
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
June 03, 2024
Via
Benzinga
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
June 02, 2024
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences
May 30, 2024
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Expert Ratings For Caribou Biosciences
May 16, 2024
Via
Benzinga
Attention Biotech Investors - Stocks To Watch
May 16, 2024
Via
Benzinga
3 Underappreciated Stocks That Could 10x in 10 Years
May 12, 2024
Via
InvestorPlace
CRBU Stock Earnings: Caribou Biosciences Misses EPS, Misses Revenue for Q1 2024
May 07, 2024
Via
InvestorPlace
Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
May 07, 2024
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Caribou Biosciences to Participate in Upcoming Investor Conferences
May 01, 2024
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Caribou, Verrica, and Playstudios on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
April 27, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
April 15, 2024
From
Caribou Biosciences, Inc.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.